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Background: Sulphadoxine-pyrimethamine (SP) is the recommended drug for intermittent preventive treatment in
pregnancy (IPTp) in most African countries, including Zambia. However, malaria is still one of the leading causes of
morbidity and mortality in pregnant women despite reports of greater than 50% of women taking at least two doses of
SP in IPTp. Studies have shown that resistance to SP is associated with mutations in the dhfr and dhps gene of
Plasmodium falciparum. This study examined the prevalence of dhfr and dhps polymorphisms in P. falciparum found in
pregnant women of Nchelenge district.
Method: This cross-sectional study was conducted in 2013 in Nchelenge, a holoendemic area with malaria prevalence
estimated at 50% throughout the year. Three rural health centres were randomly selected and a census survey carried
out at each health centre. A questionnaire was administered and malaria testing done using RDT and microscopy,
with collection of a dried blood spot. A chelex extraction was done to extract parasite DNA from dried blood spots
followed by nested PCR and enzyme restriction digestion.
Results: Of the enrolled participants (n = 375), the median age of the women was 23. The prevalence of malaria by PCR
was 22%. The PCR positive samples examined (n = 72) showed a high prevalence of dhfr triple (Asn-108 + Arg-59 + Ile-59)
mutant (68%) and dhps double (Gly -437 + Glu-540) mutant (21%). The quintuple haplotype was found in 17%
with 2 samples with an additional Gly-581mutation. In addition 6% mutations at Val-16 were found and none found at
Thr-108 respectively, these both confer resistance to cycloguanil. Multivariate analysis showed that there was an
association between malaria and women aged 30-34 years old p < 0.05(AOR: 0.36) at 95% CI.
Conclusion: This study showed a high number of mutations in the dhfr and dhps genes. The high malaria endemicity in
the general population of this area may have contributed to the high prevalence of resistant parasites in pregnant
women, suggesting a need to examine the efficacy of SP given that it is the only approved drug for IPTp in Zambia.
Keywords: Zambia, dhfr, dhps, Malaria in pregnancy, SPBackground
Malaria remains a major cause of death predominantly
in sub-Saharan Africa. Statistics by the World Health
Organization attribute an estimated 627,000 deaths to this
disease in 2012 alone [1]. Children under five and preg-
nant women in high transmission and impoverished areas
are at most risk of the disease. Over 30 million pregnant
women are estimated to be at risk of Plasmodium* Correspondence: siame_mwiche@yahoo.com
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unless otherwise stated.falciparum malaria in sub-Saharan Africa annually [2]. The
pathological effects of malaria adversely affect pregnancy
outcome. The unborn child is at increased risk of prema-
ture and still-birth, low birth weight, congenital malaria, an-
aemia and impaired foetal growth [3-5]. Epidemiological
settings and host immunity greatly influence the clinical
presentation of pregnancy-associated malaria [6-9].
Zambia has achieved over 50% reduction in malaria
prevalence in the past decade [10]. However, the challenge
remains, as malaria is still one of the leading causes of
morbidity and mortality responsible for at least 36% of
hospital admissions and 20% of maternal mortality [11].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 General characteristics of pregnant women of
Nchelenge district (n = 375), 2013
Characteristic n or %
Median age 23 years




No SP intake 15%
>1 dose of SP 64%
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by the World Health Organization for intermittent pre-
ventive treatment in pregnancy (IPTp) [12]. IPTp is made
available through antenatal care (ANC) at government
health facilities and an overall increase in access to ITNs,
IRS and IPTp has been reported nationwide [13-15].
In Zambia, IPTp was adopted in 2003. It is administered
presumptively three months after quickening (16-26 weeks)
[16]. The pregnant woman is given one dose (each contain-
ing 500 mg of sulphadoxine and 25 mg pyrimethamine) for
every ante natal care visit one month apart, under direct
observation of the health worker [17]. Prior to the universal
adoption of SP in IPTp randomized controlled trials have
showed that SP supplemented with iron decreases the risk
of placental parasitaemia, maternal anaemia and low birth
weight [18-20].
Drug resistance is one of the greatest challenges of mal-
aria control programmes. Hence, while SP remains ideal for
IPTp, in stable transmission areas, increasing resistance has
been reported [21,22]. SP resistance is linked to point muta-
tions in the parasite genome specifically the dihydrofolate
reductase (dhfr) and dihydpteroate synthetase (dhps) genes.
Mutations in dhfr confer resistance to pyrimethamine while
mutations in dhps confer resistance to sulphadoxine and
other sulpha drugs. There are variations in SP mutations,
single, double or triple - the more mutations, the stronger
the resistance. The dhfr triple mutant (Asn-108 + Ile-51 +
Arg-59) and dhps double mutant (Gly-437 +Glu-540) have
been strongly associated with potential resistance in sub-
Saharan Africa [23,24].
A study done in 2006 in six districts in the general
population of Zambia showed variation of rates of resist-
ance to SP with mutated dhfr frequency ranging from
71-92% and 39-71% frequency for the double mutant
dhps, respectively [25]. Therefore, there is a need for
close monitoring and surveillance of the efficacy of SP in
pregnant women. This study aimed to investigate the
presence of malaria in pregnancy, associated risk factors
and determine the prevalence of molecular markers that
confer resistance to SP in a highly endemic area.
Methods
Design and sampling procedures
This cross-sectional study was conducted in Nchelenge dis-
trict, Luapula province, Zambia in February to April 2013.
The population of Nchelenge is estimated at 180,000 and
the inhabitants are mostly fishermen and peasant farmers.
Nchelenge has one first level referral hospital St Paul’s
Mission hospital, ten rural health centres and three health
posts. This is a holoendemic area of malaria transmission
with an estimated 50% confirmed cases throughout the
year, hence transmission is throughout the year. An esti-
mated 80% of recorded deaths are attributed to malaria
with the most affected being children under five yearsof age and pregnant women. The target population of
this study was pregnant women who were residents of
Nchelenge and attended antenatal care at any of the
three health facilities selected for the study (Table 1).
Parental consent and child assent was obtained for
those below 18 years old. Non-pregnant women, preg-
nant women not resident in the study sites or those
within the catchment area but severely ill, were not eli-
gible to be included in the study.
Multi-stage sampling was employed. The district was
conveniently selected while simple random sampling using
Microsoft Excel was used to select the three rural health
centres (RHCs) out of 14 in the district and these three
were the sites chosen for the study. The rural health
centres selected were Kabuta, Nchelenge and Kashikishi
RHC. Consenting individuals were included in a census
survey from the rural health centres. Hence, all pregnant
women who came to the centre for antenatal care, regard-
less of whether for re-visits or first attendance, were eligible
to be included in the study.
The prevalence of malaria in pregnant women was as-
sumed to be 50%, which is the prevalence for the general
population in Nchelenge. The calculated total sample
size was 384 with a power of 80 at 95% CI.
Data collection
The data collection tool used in this study was a structured
questionnaire to document demographic data and risk fac-
tors for the presence of malaria. To validate the data collec-
tion tool pre-testing of the questionnaire was done in two
ways: the tool was pre-tested to ensure clarity of questions
in English and then for consistency, precision, clarity of
questions and correct translations in Bemba. Necessary ad-
justments and revisions were made based on the pre-test
results.
Laboratory methods
The eligible pregnant women were screened for malaria
and anaemia on the scheduled ante-natal care day. Malaria
was defined as a positive laboratory test for P. falciparum
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microlitres of venous blood was collected from each partici-
pant by a single finger prick. A rapid diagnostic test (RDT)
and microscopy was used to test for malaria. The RDT used
detects the antigen histidine rich protein II (HRP II) found
on the parasite surface, the test kits brand was the Standard
Diagnostics Bioline Malaria antigen Pf test (SD-p.fTM) man-
ufactured by Standard Diagnostics Inc., South Korea. The
test results were ready within 15 minutes. Thick blood
smears were collected on microscope slides for later read-
ing by a microscopist.
Dried blood spots (DBS) were also collected on Whatman
3MM filter paper at the same time as the RDT and
thick smear. Plasmodium falciparum DNA was ex-
tracted from the DBS by a chelex protocol and ampli-
fied by polymerase chain reaction (PCR) followed by
restriction enzyme digestion. Mutations were defined
as the detection of polymorphisms in the dhfr gene specific-
ally at Asn-108, Arg-59, Ile-59 and dhps Gly-437, Glu-540
and Gly-581 mutation. Mixed infections were those that
showed both sensitive and resistant parasite strains while
sensitive strains were parasites that showed no polymor-
phisms in the region of interest after restriction digestion.
Quality assurance was done at Tulane University, School of
Public Health and Tropical Medicine in the Kumar Labora-
tory. Positive samples (n = 10) were randomly selected and
PCR was done followed by restriction digestion with en-
zymes BStNI, AluI and BSrI. The results were similar to
those initially obtained hence results were reproducible and
reliable.Data analysis
Analysis was done using Stata version 12.2. Variables
were defined, descriptive statistics; means, medians,
standard deviations and odds ratios were used to assess
the data. The factors examined were age, marital status,
gravidity, education level, ITN ownership and usage,
malaria knowledge, medical history and SP intake.
These were self reported and SP intake was confirmed
by medical records. Chi square was used to determine
the association between malaria and each of the associ-
ated factors. Significance (p-value) was set at 5% with a
confidence interval at 95%. Multivariate analysis using
logistic regression was done for adjustments, to control
for confounding and to examine the odds ratios for
malaria prevalence in relation to each of the risk
factors.Ethics
Ethical approval was sought from the University of Zambia
Biomedical Research Ethics Committee (UNZABREC) and
granted in February, 2013 (IRB004-11-12).Results
Population characteristics
A total number of 400 participants were enrolled in this
study, of these 375 had complete data. The median age
of the participants was 23 years old (IQR 20-24). The
median gestational stage was 24-36 weeks. Of the
women enrolled 57% reported to have had a primary
education while only 3.2% reported a college/university
attainment. Of these women 15% had not received any
SP at the time of enrollment. The major source of non-
participation was refusal (<5%) and incomplete data.
Malaria infection risk factors
The prevalence of malaria by rapid diagnostic test was
30%, by microscopy prevalence was 15% and 22% by
PCR. The rapid diagnostic test is an antigen-based test
and may remain positive two weeks after treatment,
hence may result in false positives. Using Chi square
analysis, significant results were obtained for malaria
symptom knowledge and age. Over 75% of women with
symptom knowledge of malaria had taken medication in
the last malaria infection, with the greatest proportion
(50%) having taken artemether-lumefantrine (Coartem®).
In terms of insecticide-treated net distribution, 74% of
the women reported to own at least one net in their
household although the results suggest that there was no
association with malaria. Using multivariate analysis
none of the factors were significantly associated with
malaria except age. Women aged 30-34 were 64% less
likely to have malaria compared to those in the reference
group 14-18 years old (AOR: 0.36 95% CI).
Genotyping
Of the PCR positives, 72 were genotyped using restriction
fragment length polymorphism (RFLP) for the presence of
mutations at the different loci. The prevalence of dhfr and
dhps mutations are shown in Figures 1 and 2. The preva-
lence of the dhfr triple mutant (Asn-108 + Ile-51 +Arg-59)
was 68% and dhps double mutant (Gly-437 +Glu-540) was
21%. The quintuple mutant was present in 17% (n = 12) of
the samples and the sextuple mutant was present in 3%
(n = 2) of the samples. The figures show additional co-
dons at Val-16 and dhps mutation at codon 436. There
was no association between SP intake and genotypes
present.
Discussion
This study documents high malaria prevalence and antifo-
late resistance mutations in pregnant women in a holo en-
demic area. It is important to note that >60% of women
who were found with malaria had taken at least one dose of
SP. However, with multivariate analysis there was no associ-
ation between presence of malaria and any of the associated
risk factors except age, hence the association found with
Figure 1 Plasmodium falciparum DHFR mutations (n = 72) in pregnant women of Nchelenge district, Zambia, 2013.
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analysis on predictors of malaria prevalence suggests an as-
sociation between malaria prevalence and women aged
30-34 years compared to those women aged 14-18 years
old. This may be due to a protective effect reported in other
studies that older women who are likely to have had more
than one previous pregnancy (multigravidae) are less likely
to have malaria compared to those who have not had chil-
dren previously (primigravidae) [25].
Possible bias due to non-participation may have oc-
curred as this study was based exclusively at the health
centres thereby excluding those pregnant women who
did not attend antenatal clinic and who may have a
different profile from those that do. Another study
limitation was that clinical efficacy of SP was not de-
termined in order to assess treatment failure, and the
data collected including when the last malaria medica-
tion was taken may be subject to recall bias.Figure 2 Plasmodium falciparum dhps mutations (n = 72) in Plasmodium falcipThe results obtained show high levels of dhfr muta-
tions indicating mostly pyrimethamine resistance but
also a higher emergence of mutations Val-16 which is an
indication of resistance to cycloguanil and a higher
emergence of mutations at dhps 581 than previously re-
ported. Another study conducted in Mansa, Zambia in
pregnant women showed 63% had quintuple mutants
while only two had an additional mutation at the Gly-
581 loci. The treatment failure recorded in the study
was 22%. This shows that the dhps mutations are be-
coming more common and there has been an escalation
in the mutations in this population. This is consistent
with other studies that have shown that in hyperendemic
areas with high rate of transmission as is the case for
Nchelenge, resistant parasites have a tendency to in-
crease and contribute to treatment failure [26]. SP has
been in use for over two decades in Zambia and due to
drug pressure parasite resistance is expected to be higharum parasites in pregnant women of Nchelenge district Zambia, 2013.
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has been used for even shorter periods of time. Data
from southern Zambia showed that by 2006, the preva-
lence of dhfr and dhps mutants had escalated rapidly
since 1988, and that the quintuple (dhfr triple + dhps
double) mutant associated with highest levels of SP clin-
ical failure was starting to be seen (6.5%) [27].
Studies done in Tanzania have shown an emergence of
the presence of the dhps triple mutant and suggested
that IPTp with SP may not improve overall pregnancy
outcome [28]. Furthermore conflicting results have been
found with some studies showing increased prevalence
of dhfr and dhps mutations while still others have found
that SP IPTp is effective [29,30].
High prevalence of multiple mutants raises concerns
as these have been shown to correlate with therapeutic
or clinical failures. Therefore there is need to explore
other drugs as options for IPTp.
Conclusion
This study shows a high prevalence of malaria in preg-
nant women of Nchelenge district, despite reported use
of SP-IPTp. This may be due to the high parasite resist-
ance mutations to the drug as was evident in this study.
The research implications are that there is need to con-
duct further high powered studies to determine efficacy
and parasite clearance rates using SP-IPTp and also
begin to explore alternative avenues for drugs to be used
in IPTp if it is to be beneficial to this population.
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